Lake Street Maintains Buy on Insight Molecular, Lowers Price Target to $9
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Lake Street analyst Thomas Flaten maintains Insight Molecular (NASDAQ:IMDX) with a Buy and lowers the price target from $12 to $9.
Lake Street analyst Thomas Flaten maintains Insight Molecular (NASDAQ:IMDX) with a Buy and lowers the price target from $12 to $9.
More on IMDX
Benzinga
Insight Molecular Diagnostics Enrolls First Several Patients In Its GALACTIC Study Evaluating GraftAssure Molecular Test For Monitoring Rejection In Kidney Transplant RecipientsThis study serves to introduce GraftAssure technology to new transplant centers and additionally builds validation data ahead of potential FDA authorization of GraftAssureDx, a kitted version of the…
